Back

Clinical implications for patients at persistent ASCVD risk

31 August 2019 (15:30 - 15:55)
Organised by:
Congress Presentation Part of: Targeting of PCSK9 with siRNA for LDL-C reduction in a high-risk population Lipids ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Joseph Saseen

University of Colorado Anschutz Medical Campus, Aurora (United States of America)

4 More presentations in this session

Presentation thumbnail
Clinical trial updates
Doctor C. Ballantyne (Houston, US)
Slides Video
Presentation thumbnail
The future of lipid management: new therapies for LDL-C lowering
Doctor H. Bays (Louisville, US)
Slides Video
Presentation thumbnail
Post-activity quiz and discussion
Doctor P. MORRIS (Charleston, US)
Slides Video
Presentation thumbnail
Questions and answers / Panel discussion
Slides Video

Access the full session

Session thumbnail
Targeting of PCSK9 with siRNA for LDL-C reduction in a high-risk population

The Event

Event poster

ESC Congress 2019

31 August 2019 15:30 CET
You may be interested in
thumbnail
Congress Presentation
Lipid and secondary prevention 'up to date'
28 August 2023
thumbnail
ESC TV Today
Episode 17: Coronary sinus reducer - Best strategies to reach LDL cholesterol goals
5 June 2025
thumbnail
Congress Presentation
Boosting secondary prevention: efficacy and adherence of inclisiran in post-acute coronary syndrome very high-risk patients
3 April 2025
thumbnail
Congress Presentation
Characterization of lipidic coronary atheroma under control of low-density lipoprotein <1.8 mmol/l and lipoprotein (a) <50 mg/dl in patients with coronary artery disease
26 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources